K. Kosmatopoulos

665 total citations
17 papers, 551 citations indexed

About

K. Kosmatopoulos is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, K. Kosmatopoulos has authored 17 papers receiving a total of 551 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Immunology, 9 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in K. Kosmatopoulos's work include Immunotherapy and Immune Responses (13 papers), vaccines and immunoinformatics approaches (5 papers) and RNA Interference and Gene Delivery (5 papers). K. Kosmatopoulos is often cited by papers focused on Immunotherapy and Immune Responses (13 papers), vaccines and immunoinformatics approaches (5 papers) and RNA Interference and Gene Delivery (5 papers). K. Kosmatopoulos collaborates with scholars based in France, Greece and United States. K. Kosmatopoulos's co-authors include Muhammad Zaeem Noman, Michael A. Curran, Salem Chouaı̈b, Jean‐Claude Manuguerra, Isabelle Vergnon, Nicole Riché, Sophie Tourdot, Mohammed Oukka, S. Orbach‐Arbouys and Αthanasios Kotsakis and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Cancer Research.

In The Last Decade

K. Kosmatopoulos

17 papers receiving 536 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K. Kosmatopoulos France 7 292 215 146 131 90 17 551
Joanna Stanson United States 15 436 1.5× 339 1.6× 205 1.4× 156 1.2× 42 0.5× 20 715
Dawson Knoblock United States 7 403 1.4× 194 0.9× 337 2.3× 69 0.5× 28 0.3× 8 695
Anna Bergsmedh Sweden 6 176 0.6× 481 2.2× 114 0.8× 247 1.9× 36 0.4× 7 624
Olga Blomberg Netherlands 9 303 1.0× 181 0.8× 293 2.0× 33 0.3× 56 0.6× 9 583
John Copier United Kingdom 15 449 1.5× 379 1.8× 270 1.8× 52 0.4× 41 0.5× 29 902
Rosa Wainstok Argentina 10 574 2.0× 214 1.0× 317 2.2× 39 0.3× 57 0.6× 17 727
Philaretos C. Kousis United States 9 261 0.9× 187 0.9× 148 1.0× 84 0.6× 304 3.4× 10 712
Samantha M. Morrissey United States 8 364 1.2× 467 2.2× 215 1.5× 271 2.1× 89 1.0× 13 783
Virginia Cecconi Switzerland 12 680 2.3× 310 1.4× 357 2.4× 67 0.5× 29 0.3× 21 964

Countries citing papers authored by K. Kosmatopoulos

Since Specialization
Citations

This map shows the geographic impact of K. Kosmatopoulos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Kosmatopoulos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Kosmatopoulos more than expected).

Fields of papers citing papers by K. Kosmatopoulos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Kosmatopoulos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Kosmatopoulos. The network helps show where K. Kosmatopoulos may publish in the future.

Co-authorship network of co-authors of K. Kosmatopoulos

This figure shows the co-authorship network connecting the top 25 collaborators of K. Kosmatopoulos. A scholar is included among the top collaborators of K. Kosmatopoulos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Kosmatopoulos. K. Kosmatopoulos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Gridelli, Cesare, Tudor–Eliade Ciuleanu, M. Dómine Gómez, et al.. (2017). Randomized double blind phase IIb trial in advanced NSCLC patients who did not progress after first line platinum based chemotherapy: Vx-001, a therapeutic cancer vaccine, vs placebo as maintenance therapy. Annals of Oncology. 28. v638–v638. 3 indexed citations
2.
Chouaı̈b, Salem, Muhammad Zaeem Noman, K. Kosmatopoulos, & Michael A. Curran. (2016). Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer. Oncogene. 36(4). 439–445. 286 indexed citations
3.
Kotsakis, Αthanasios, Eleni‐Kyriaki Vetsika, Dora Hatzidaki, et al.. (2011). Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study. Annals of Oncology. 23(2). 442–449. 44 indexed citations
4.
Kotsakis, Αthanasios, et al.. (2008). Clinical and immunologic response of patients with advanced solid tumors vaccinated with an optimized cryptic hTERT peptide (Vx-001). Journal of Clinical Oncology. 26(15_suppl). 3030–3030. 2 indexed citations
5.
Kosmatopoulos, K., et al.. (2007). Vaccination of patients with advanced non-small cell lung cancer with an optimized cryptic hTERT peptide (Vx-001). Journal of Clinical Oncology. 25(18_suppl). 7642–7642. 2 indexed citations
6.
Kosmatopoulos, K., et al.. (2006). Safety and immunogenicity of the optimized cryptic peptide TERT572Y in patients with advanced cancer : a phase I clinical study. Cancer Research. 66. 334–334. 2 indexed citations
7.
Mavroudis, Dimitriοs, Sébastien Cornet, Peggy Kanellou, et al.. (2006). A Phase I Study of the Optimized Cryptic Peptide TERT<sub>572Y</sub> in Patients with Advanced Malignancies. Oncology. 70(4). 306–314. 47 indexed citations
8.
Kosmatopoulos, K., et al.. (2006). Clinical efficacy and immunogenicity of the optimized cryptic peptide TERT572Y vaccine (Vx-001) in patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 24(18_suppl). 17069–17069. 2 indexed citations
9.
Kosmatopoulos, K., et al.. (2005). Safety and immunogenicity of the optimized cryptic peptide TERT572Y in patients with advanced malignancies: A Phase I clinical study. Journal of Clinical Oncology. 23(16_suppl). 2579–2579. 2 indexed citations
10.
Scardino, Antonio, Pierpaolo Correale, Hüseyin Firat, et al.. (2003). In vivo study of the GC90/IRIV vaccine for immune response and autoimmunity into a novel humanised transgenic mouse. British Journal of Cancer. 89(1). 199–205. 15 indexed citations
11.
Nizard, Philippe, et al.. (2001). [Anchoring cytokines to cancer cells using diphtheria toxin: better than immunotherapy by gene transfer?].. PubMed. 195(3). 229–34. 2 indexed citations
12.
Tourdot, Sophie, Mohamed Oukka, Jean‐Claude Manuguerra, et al.. (1997). Chimeric peptides: a new approach to enhancing the immunogenicity of peptides with low MHC class I affinity: application in antiviral vaccination. The Journal of Immunology. 159(5). 2391–2398. 41 indexed citations
13.
Oukka, Mohammed, Jean‐Claude Manuguerra, Sophie Tourdot, et al.. (1996). Protection against lethal viral infection by vaccination with nonimmunodominant peptides. The Journal of Immunology. 157(7). 3039–3045. 76 indexed citations
14.
Oukka, Mohammed, et al.. (1995). The J alpha segment contributes to the affinity of V beta 6+ cells for vSAG-7 (Mls-1a) presented by I-A molecules.. PubMed. 84(4). 609–18. 2 indexed citations
15.
Cabaniols, Jean‐Pierre, et al.. (1991). Mechanism of hybrid resistance. The role of a natural antibody in parental bone marrow cell rejection. The Journal of Immunology. 146(3). 860–864. 1 indexed citations
16.
17.
Kosmatopoulos, K., et al.. (1987). Anti-receptor anti-MHC cytotoxic T lymphocytes: their role in the resistance to graft vs host reaction.. The Journal of Immunology. 138(4). 1038–1041. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joanna Stanson Breakdown of academic impact, for papers by Dawson Knoblock Breakdown of academic impact, for papers by Anna Bergsmedh Breakdown of academic impact, for papers by Olga Blomberg Breakdown of academic impact, for papers by John Copier Breakdown of academic impact, for papers by Rosa Wainstok Breakdown of academic impact, for papers by Philaretos C. Kousis Breakdown of academic impact, for papers by Samantha M. Morrissey Breakdown of academic impact, for papers by Virginia Cecconi
Rankless by CCL
2026